ImmunoPrecise Antibodies (NASDAQ:IPA) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 10 percent. This is a 10 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $6.13 million which missed the analyst consensus estimate of $6.44 million by 4.88 percent. This is a 0.41 percent decrease over sales of $6.15 million the same period last year.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。